C eliac disease is increasingly detected by family physicians or gastroenterologists using immunoglobulin A antitissue transglutaminase antibody serology, which has operating characteristics perfectly suited for a screening test. Whether a biopsy is still required to confirm the diagnosis is debated, but in clinical practice, an endoscopy and biopsy is often performed to confirm the diagnosis (1). The serological titres are then often followed-up to assess adherence to gluten-free diet and adequate resolution of celiac disease by diet.
Upper endoscopy is a common procedure performed by gastroenterologists to investigate dyspepsia, dysphagia and other upper gastrointestinal symptoms. This offers an opportunity to obtain duodenal biopsies to establish or exclude the diagnosis of celiac disease. However, this approach requires considerable investment of time and resources by pathologists.
An important question, therefore, is whether duodenal biopsies should be routinely obtained at the time of endoscopy. Celiac disease may be associated with a multitude of symptoms and presentations such as bloating, diarrhea, abdominal discomfort, fatigue, weight loss, iron deficiency anemia, bone disease, skin disorders and abnormal liver function tests. Patients may also be completely asymptomatic but, of course, such patients generally do not present for upper endoscopy. While the prevalence of celiac disease continues to increase globally, a significant proportion of celiac disease patients remain undiagnosed. In the current issue of the Canadian Journal of Gastroenterology, Freeman (2) (pages 409-413) reports a long experience of diagnosing celiac disease using duodenal biopsies during upper endoscopy and the resultant increased diagnosis of celiac disease in the population. Duodenal bulb biopsies may increase diagnostic yield because villous atrophy may be patchy (3). A recent study has shown that modern high-definition endoscopic techniques with image enhancement may be very accurate in diagnosing villous atrophy (4). It may, therefore, be possible to only perform confirmatory duodenal biopsies, two from the duodenal bulb and four to six from the distal duodenum, where villous atrophy is suspected at high-definition endoscopy, with image enhancement techniques built into modern endoscopes. Marsh modified type 1 histology grade may, of course, miss recognition by endoscopic techniques. Endoscopic and histological demonstration of villous atrophy alone need to be distinguished from other causes of villous atrophy.
Therefore, when a patient is referred for upper endoscopy to confirm the diagnosis of celiac disease (such as in patients with positive celiac serology) or exclude celiac disease in patients with suspected celiac disease, it is, of course, mandatory to obtain biopsies from a second part of the duodenum and from the duodenal bulb. In patients referred for endoscopy to investigate upper gastrointestinal symptoms, but not suspected to have celiac disease, it may be acceptable to inspect the duodenum with high-definition endoscopy and imageenhancement techniques, and obtain biopsies if villous atrophy is detected (Box 1, Figure 1) . However, standard white-light endoscopy alone will not be able to assess duodenal villous architecture. If biopsies at endoscopy confirm the diagnosis of celiac disease in patients who did not have celiac serology already performed, it will be essential to determine immunoglobulin A antitissue transglutaminase titres.
BOX 1 Endoscopic assessment of celiac disease
Biopsies from distal duodenum 
